Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0452 Transporter Info
Gene Name	SLC6A2
Transporter Name	Sodium-dependent noradrenaline transporter
Gene ID	6530
UniProt ID	P23975

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Cocaine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cocaine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cocaine results in decreased activity of SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Cocaine results in increased expression of SLC6A2 protein			[86]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Fluoxetine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fluoxetine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Amphetamine inhibits the reaction nisoxetine binds to SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Amphetamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Amphetamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Amphetamine results in decreased activity of SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Amphetamine results in decreased expression of SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A2 SNP affects the susceptibility to Amphetamine			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A2 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dextroamphetamine results in decreased activity of SLC6A2 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A2 gene SNP affects the susceptibility to Dextroamphetamine			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A2 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased uptake of Norepinephrine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Norepinephrine inhibits the reaction nisoxetine binds to SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Norepinephrine results in decreased activity of SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A2 mutant form results in decreased uptake of Norepinephrine			[93]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A2 protein promotes the reaction Norepinephrine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A2 protein results in increased uptake of Norepinephrine			[64]
Regulation Mechanism				Transcription Factor Info
1-Methyl-4-phenylpyridinium	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium affects the expression of SLC6A2 mRNA			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	para-methyl-4-methylaminorex inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
4-fluoroamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-fluoroamphetamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-fluoroamphetamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
4-methoxymethamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methoxymethamphetamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-methoxymethamphetamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
4-methylaminorex	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methylaminorex results in decreased activity of SLC6A2 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A2 protein results in increased uptake of 4-methylaminorex			[64]
Regulation Mechanism				Transcription Factor Info
5-(2-aminopropyl)benzofuran	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
Arsenic Trioxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A2 protein results in decreased susceptibility to Arsenic Trioxide			[82]
Regulation Mechanism				Transcription Factor Info
belinostat	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	belinostat results in increased expression of SLC6A2 mRNA			[37]
Regulation Mechanism				Transcription Factor Info
Benzo(a)pyrene	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC6A2 promoter			[83]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in increased methylation of SLC6A2 exon			[83]
Regulation Mechanism				Transcription Factor Info
bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC6A2 gene			[84]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC6A2 gene			[85]
Regulation Mechanism				Transcription Factor Info
Fonofos	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fonofos results in increased methylation of SLC6A2 promoter			[89]
Regulation Mechanism				Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC6A2 gene			[84]
Regulation Mechanism				Transcription Factor Info
Hydralazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydralazine co-treated with Valproic Acid results in increased expression of SLC6A2 mRNA			[90]
Regulation Mechanism				Transcription Factor Info
indatraline	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	indatraline inhibits the reaction SLC6A2 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
Monensin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
nisoxetine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amphetamine inhibits the reaction nisoxetine binds to SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Norepinephrine inhibits the reaction nisoxetine binds to SLC6A2 protein			[32]
Regulation Mechanism				Transcription Factor Info
N-Methyl-3,4-methylenedioxyamphetamine	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased import of Biogenic Monoamines analog			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased import of Fluorescent Dyes			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A2 protein results in increased uptake of Norepinephrine			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	N-Methyl-3,4-methylenedioxyamphetamine results in decreased activity of SLC6A2 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A2 gene SNP affects the susceptibility to N-Methyl-3,4-methylenedioxyamphetamine			[92]
Regulation Mechanism				Transcription Factor Info
Nortriptyline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A2 gene polymorphism affects the susceptibility to Nortriptyline			[94]
Regulation Mechanism				Transcription Factor Info
Octopamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A2 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
para-methyl-4-methylaminorex	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	para-methyl-4-methylaminorex binds to SLC6A2 protein			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	para-methyl-4-methylaminorex inhibits the reaction SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[78]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	para-methyl-4-methylaminorex results in decreased activity of SLC6A2 protein			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A2 protein results in increased uptake of para-methyl-4-methylaminorex			[64]
Regulation Mechanism				Transcription Factor Info
Parathion	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Parathion results in increased methylation of SLC6A2 promoter			[89]
Regulation Mechanism				Transcription Factor Info
phenethylamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A2 protein promotes the reaction phenethylamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
pirinixic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pirinixic acid binds to and results in increased activity of PPARA protein which results in decreased expression of SLC6A2 mRNA			[96]
Regulation Mechanism				Transcription Factor Info
Selenium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Selenium results in decreased expression of SLC6A2 mRNA			[61]
Regulation Mechanism				Transcription Factor Info
Serotonin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A2 protein promotes the reaction Serotonin results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC6A2 mRNA			[66]
Regulation Mechanism				Transcription Factor Info
terbufos	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	terbufos results in increased methylation of SLC6A2 promoter			[89]
Regulation Mechanism				Transcription Factor Info
tryptamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A2 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
Tyramine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desipramine inhibits the reaction SLC6A2 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A2 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A2 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[87]
Regulation Mechanism				Transcription Factor Info
Valproic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydralazine co-treated with Valproic Acid results in increased expression of SLC6A2 mRNA			[90]
Regulation Mechanism				Transcription Factor Info
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 results in increased methylation of SLC6A2 intron			[80]
Regulation Mechanism				Transcription Factor Info
Carcinogen
Nickel	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nickel results in decreased expression of SLC6A2 mRNA			[91]
Regulation Mechanism				Transcription Factor Info
Nanoparticle
perfluoro-n-nonanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluoro-n-nonanoic acid affects the methylation of SLC6A2 gene			[95]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Cocaine	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the transportation of Dopamine by SLC6A2			[1]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)1-NET
DT Modulation2	Cocaine inhibits the transportation of Mazindol by SLC6A2			[2]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation3	Cocaine inhibits the transportation of Norepinephrine by SLC6A2			[3]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation4	Cocaine inhibits the transportation of RTI-55 by SLC6A2			[2], [4]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation5	Cocaine inhibits the activity of SLC6A2			[5], [6]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation6	Cocaine inhibits the activity of SLC6A2			[1]
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)1-NET
Fluoxetine	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluoxetine inhibits the transportation of Dopamine by SLC6A2			[7]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET
DT Modulation2	Fluoxetine inhibits the transportation of Norepinephrine by SLC6A2			[3], [8], [9]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation3	Fluoxetine inhibits the activity of SLC6A2			[13], [14]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Mazindol	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mazindol inhibits the transportation of Mazindol by SLC6A2			[2]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Mazindol inhibits the transportation of RTI-55 by SLC6A2			[2]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation3	Mazindol inhibits the activity of SLC6A2			[5]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Desipramine	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desipramine inhibits the transportation of Nisoxetine by SLC6A2			[11]
Affected Drug/Substrate	Nisoxetine	Modulation Type	Inhibition
DT Modulation2	Desipramine inhibits the transportation of Norepinephrine by SLC6A2			[12]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
DT Modulation3	Desipramine inhibits the activity of SLC6A2			[15]
Cell System	Madin-Darby Canine Kidney (MDCK) cells-NET
Reboxetine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Reboxetine inhibits the transportation of Nisoxetine by SLC6A2			[18], [19]
Affected Drug/Substrate	Nisoxetine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Reboxetine inhibits the activity of SLC6A2			[23]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Duloxetine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Duloxetine inhibits the transportation of Nisoxetine by SLC6A2			[19]
Affected Drug/Substrate	Nisoxetine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Duloxetine inhibits the activity of SLC6A2			[20], [21], [22]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Amitriptyline	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitriptyline inhibits the transportation of Norepinephrine by SLC6A2			[3]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Amitriptyline inhibits the activity of SLC6A2			[25], [26]
Venlafaxine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Venlafaxine inhibits the transportation of Norepinephrine by SLC6A2			[3], [9]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Venlafaxine inhibits the activity of SLC6A2			[22]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
4-Fluoroamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.2 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
4-Fluoromethamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoromethamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.22 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
alpha-Pyrrolidinopentiophenone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	alpha-Pyrrolidinopentiophenone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.02 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Amphetamine	7 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.07 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Ephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.32 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Methamphetamine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methamphetamine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.14 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Citalopram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the transportation of Dopamine by SLC6A2			[7], [27]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET
Dextroamphetamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dextroamphetamine inhibits the transportation of Norepinephrine by SLC6A2			[3]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Dopamine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dopamine inhibits the activity of SLC6A2			[28]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Methylphenidate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylphenidate inhibits the activity of SLC6A2			[29]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Bupropion	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bupropion inhibits the activity of SLC6A2			[6]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Protriptyline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Protriptyline inhibits the activity of SLC6A2			[30]
Cell System	Chinese hamster ovary (CHO) cells-NET
Desvenlafaxine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desvenlafaxine inhibits the activity of SLC6A2			[22]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Norepinephrine	7 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Norepinephrine inhibits the expression of SLC6A2			[32]
Carmustine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carmustine increases the expression of SLC6A2			[33]
Copper Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate increases the expression of SLC6A2			[35]
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zidovudine increases the expression of SLC6A2			[36]
Belinostat	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Belinostat increases the expression of SLC6A2			[37]
Imipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Imipramine inhibits the activity of SLC6A2			[38], [39]
Atomoxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atomoxetine inhibits the activity of SLC6A2			[40], [41]
Amfepramone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amfepramone inhibits the activity of SLC6A2			[42], [43]
Sibutramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sibutramine modulates the activity of SLC6A2			[44]
Tapentadol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tapentadol modulates the activity of SLC6A2			[45]
Trimipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trimipramine inhibits the activity of SLC6A2			[46]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the activity of SLC6A2			[47]
Maprotiline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Maprotiline inhibits the activity of SLC6A2			[48]
Amoxapine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amoxapine inhibits the activity of SLC6A2			[49]
Desvenalfaxine succinate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desvenalfaxine succinate inhibits the activity of SLC6A2			[50]
Levomilnacipran	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levomilnacipran modulates the activity of SLC6A2			[51]
Phenmetrazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenmetrazine inhibits the activity of SLC6A2			[52]
Milnacipran	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Milnacipran inhibits the activity of SLC6A2			[53]
Phentermine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phentermine inhibits the activity of SLC6A2			[54]
Iobenguane I-123	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Iobenguane I-123 inhibits the activity of SLC6A2			[55]
Paroxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Paroxetine inhibits the activity of SLC6A2			[56]
Haloperidol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Haloperidol inhibits the activity of SLC6A2			[57]
Clomipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clomipramine inhibits the activity of SLC6A2			[58]
Vorinostat	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vorinostat induces the activity of SLC6A2			[59]
Drug Marketed but not Approved by US FDA
Zinc Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zinc Sulfate increases the expression of SLC6A2			[34]
Drug in Phase 4 Trial
Hypericum	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hypericum inhibits the activity of SLC6A2			[74]
Drug in Phase 3 Trial
Vitamin E	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vitamin E inhibits the expression of SLC6A2			[61]
Triclosan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Triclosan increases the expression of SLC6A2			[63]
Bupropion + naltrexone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bupropion + naltrexone inhibits the activity of SLC6A2			[67]
Dasotraline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dasotraline inhibits the activity of SLC6A2			[68]
Roclatan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Roclatan modulates the activity of SLC6A2			[69]
Suronacrine maleate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Suronacrine maleate modulates the activity of SLC6A2			[72]
Bicifadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bicifadine modulates the activity of SLC6A2			[73]
Amitifadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitifadine inhibits the activity of SLC6A2			[75], [76]
BI 201335	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	BI 201335 inhibits the activity of SLC6A2			[77]
Drug in Phase 2 Trial
DOV 21947	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	DOV 21947 inhibits the activity of SLC6A2			[70], [71]
Drug in Phase 1 Trial
CCRIS-9277	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CCRIS-9277 inhibits the activity of SLC6A2			[64]
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite inhibits the expression of SLC6A2			[66]
Investigative Drug
Nisoxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nisoxetine inhibits the transportation of Dopamine by SLC6A2			[7]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-NET
DT Modulation2	Nisoxetine inhibits the transportation of Norepinephrine by SLC6A2			[8], [9], [10]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation3	Nisoxetine inhibits the activity of SLC6A2			[16]
Pyrovalerone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrovalerone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.05 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
DT Modulation2	Pyrovalerone inhibits the activity of SLC6A2			[24]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.16 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.97 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Methcathinone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methcathinone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.12 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Methylenedioxypyrovalerone (MDPV)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.04 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
R-Norduloxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	R-Norduloxetine inhibits the activity of SLC6A2			[31]
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Drug Withdrawn
Naphyrone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Naphyrone inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 0.11 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Natural Product
4-Fluoroephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroephedrine inhibits the transportation of Norepinephrine by SLC6A2 (IC50 = 4.5 microM)			[17]
Affected Drug/Substrate	Norepinephrine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NET
Selenium nanoparticles	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Selenium nanoparticles inhibits the expression of SLC6A2			[61]
Resveratrol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Plant Extracts co-treated with Resveratrol results in decreased expression of SLC6A2 mRNA			[97]
Regulation Mechanism				Transcription Factor Info
Acute Toxic Substance
Antimycin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Antimycin A increases the expression of SLC6A2			[65]
Health and Environmental Toxicant
1-methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-methyl-4-phenylpyridinium affects the expression of SLC6A2			[60]
Lead	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lead inhibits the expression of SLC6A2			[62]

References
1	Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
2	Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
3	An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
4	Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
5	Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
6	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
7	From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem. 2008 May 22;51(10):3045-8.
8	Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
9	Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
10	Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors. J Med Chem. 2012 Sep 27;55(18):8188-92.
11	1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. J Med Chem. 2009 Sep 24;52(18):5703-11.
12	Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J Med Chem. 2010 Jun 10;53(11):4511-21.
13	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
14	Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
15	Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8.
16	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 15;18(18):4929-31.
17	Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
18	[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
19	Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
20	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
21	N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
22	Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
23	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem. 2009 Jan 8;52(1):62-73.
24	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
25	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
26	A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
27	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
28	Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
29	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
30	First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain. J Med Chem. 2012 Apr 12;55(7):3488-501.
31	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
32	Regulation of the human norepinephrine transporter by cocaine and amphetamine. J Pharmacol Exp Ther. 2000 Dec;295(3):951-9.
33	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
34	Discrimination of vanadium from zinc using gene profiling in human bronchial epithelial cells. Environ Health Perspect. 2005 Dec;113(12):1747-54.
35	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
36	Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
37	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
38	Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83.
39	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
40	New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
41	Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
42	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
43	Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
44	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
45	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
46	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
47	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11.
48	Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
49	Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
50	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
51	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
52	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
53	Milnacipran: Beyond a Role of Antidepressant. Clin Neuropharmacol. 2009 Jun 10.
54	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
55	Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
56	Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem. 2005 Sep 22;48(19):6023-34.
57	Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
58	Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
59	Improving cytocompatibility of CdTe quantum dots by Schiff-base-coordinated lanthanides surface doping. J Nanobiotechnology. 2018 Apr 19;16(1):43.
60	Dependence on electron transport chain function and intracellular signaling of genomic responses in SH-SY5Y cells to the mitochondrial neurotoxin MPP(+). Exp Neurol. 2003 May;181(1):25-38.
61	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
62	Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox Res. 2011 Jan;19(1):1-13.
63	Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
64	Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100.
65	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615.
66	Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
67	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
68	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
69	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
70	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
71	1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors. Bioorg Med Chem. 2011 Jun 1;19(11):3451-61.
72	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
73	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
74	The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
75	1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
76	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
77	Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8.
78	The psychostimulant ()-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282-291.
79	Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol In Vitro. 2017;45(Pt 1):60-71.
80	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
81	Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl). 2009 Oct;206(3):501-11.
82	The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010;3:37.
83	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
84	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
85	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
86	Norepinephrine transporter immunoblotting and radioligand binding in cocaine abusers. J Neurosci Methods. 2005;143(1):79-85.
87	Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007;321(1):116-27.
88	Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007;61(11):1296-305.
89	DNA methylation alterations in response to pesticide exposure in vitro. Environ Mol Mutagen. 2012;53(7):542-9.
90	A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1(1):e98.
91	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362-72.
92	No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. Eur J Clin Pharmacol. 2018 Mar;74(3):275-283.
93	Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 2001;940:527-43.
94	Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 04;296(13):1609-18.
95	Gestational Perfluoroalkyl Substance Exposure and DNA Methylation at Birth and 12 Years of Age: A Longitudinal Epigenome-Wide Association Study. Environ Health Perspect. 2022;130(3):37005.
96	Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009;4(8):e6796.
97	One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69-82.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence